Vifor Pharma AG - Media releaseshttp://www.viforpharma.comIn our media releases, you will find all news around the Vifor Pharma Ltd.enSat, 25 Mar 2017 14:26:07 +0100info@viforpharma.com (Vifor Pharma AG)webmaster@galexis.com (Webmaster Vifor Pharma AG)http://www.viforpharma.com/wAssetsGroup/img/logos/viforpharma.gifVifor Pharma AG - Media releaseshttp://www.viforpharma.comWeblicationGRID60Vifor Pharma continues commitment to raise awareness of iron deficiencyFebruary 2017. This event gave Vifor Pharma the opportunity to continue its support of healthcare efforts. http://www.viforpharma.com/en/Media/mediareleases/2017/20170220_3431600258-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2017/20170220_3431600258-message.phpMon, 20 Feb 2017 06:59:14 +0100Vifor Pharma Ltd.Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc., (Nasdaq: CCXI), announced today that Vifor Pharma has gained rights to commercialize avacopan in Asia, including Japan and the Middle East. ChemoCentryx retains all rights in the United States and China. Avacopan (CCX168) is an orally-administered inhibitor of the complement 5a receptor (C5aR) and is currently in Phase III development for rare renal diseases. http://www.viforpharma.com/en/Media/mediareleases/2017/20170214_2354594350-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2017/20170214_2354594350-message.phpTue, 14 Feb 2017 07:11:02 +0100Vifor Pharma Ltd.Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseaseshttp://www.viforpharma.com/en/Media/mediareleases/2016/20161223_6763896015-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20161223_6763896015-message.phpFri, 23 Dec 2016 07:05:41 +0100Vifor Pharma Ltd.EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies http://www.viforpharma.com/en/Media/mediareleases/2016/20161207_5701381832-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20161207_5701381832-message.phpWed, 07 Dec 2016 07:43:46 +0100Vifor Pharma Ltd.Vifor Pharma leads initiatives to raise awareness of Iron Deficiency – 2nd Global Iron Deficiency Day on November 26, 2016 http://www.viforpharma.com/en/Media/mediareleases/2016/20161124_6283222694-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20161124_6283222694-message.phpThu, 24 Nov 2016 07:55:50 +0100Vifor Pharma Ltd.Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland - Swiss approval of ALOXI® for paediatric use follows EMA approval in February 2015 and FDA approval in May 2014 -Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland http://www.viforpharma.com/en/Media/mediareleases/2016/20161025_4182197418-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20161025_4182197418-message.phpTue, 25 Oct 2016 09:41:43 +0200Vifor Pharma Ltd.Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer’s proposed epoetin alfa biosimilar, Retacrit™, in the US dialysis market Vifor Pharma, a company of the Galenica group, has further expanded its Erythropoiesis Stimulating Agent (ESA) portfolio with the licensing of commercialisation rights in the US dialysis market to Pfizer’s RetacritTM, a proposed biosimilar epoetin, in the field of nephrology.http://www.viforpharma.com/en/Media/mediareleases/2016/20160524_5348226689-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20160524_5348226689-message.phpTue, 24 May 2016 06:46:14 +0200Vifor Pharma Ltd.The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure The 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure (hereafter referred to as the ESC Guidelines HF 2016) include a strong recommendation for the treatment of iron deficiency with Ferinject® in patients with systolic heart failure (HF)1.http://www.viforpharma.com/en/Media/mediareleases/2016/20160523_8372007698-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20160523_8372007698-message.phpMon, 23 May 2016 08:07:14 +0200Vifor Pharma Ltd.Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets http://www.viforpharma.com/en/Media/mediareleases/2016/20160510_7536260415-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20160510_7536260415-message.phpTue, 10 May 2016 07:20:24 +0200Vifor Pharma Ltd.Vifor Pharma appoints Colin Bond as Chief Financial Officer Vifor Pharma today announced the appointment of Colin Bond as Chief Financial Officer. http://www.viforpharma.com/en/Media/mediareleases/2016/20160510_6738242738-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20160510_6738242738-message.phpTue, 10 May 2016 07:04:45 +0200Vifor Pharma Ltd.Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE®  Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and OPKO Health (NYSE: OPK), have entered into a collaboration and license agreement for the development and commercialization of RAYALDEE® in Europe, Canada, Mexico, Australia, South Korea and certain other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency. http://www.viforpharma.com/en/Media/mediareleases/2016/20160509_5739766795-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20160509_5739766795-message.phpMon, 09 May 2016 08:08:30 +0200Vifor Pharma Ltd.Vifor Fresenius Medical Care Renal Pharma and Relypsa announce Submission of Marketing Authorisation Application Requesting European Approval of Patiromer for treatment of hyperkalemia http://www.viforpharma.com/en/Media/mediareleases/2016/20160425_5802227825-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2016/20160425_5802227825-message.phpMon, 25 Apr 2016 07:25:02 +0200Vifor Pharma Ltd.Swissmedic approves Akynzeo® (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Switzerland   - First Fixed Combination Targeting Two Key Pathways Involved in CINV -Helsinn, the Swiss Group focused on building quality in cancer care, and Vifor Pharma, announced today that Swissmedic, the Swiss Agency For Therapeutic Products, has approved Akynzeo® (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adults. The approval was granted on 6th November 2015.http://www.viforpharma.com/en/Media/mediareleases/2015/20151216_press-release-akynzeo.phphttp://www.viforpharma.com/en/Media/mediareleases/2015/20151216_press-release-akynzeo.phpWed, 16 Dec 2015 14:39:13 +0100Vifor Pharma Ltd.Soho Flordis International signs an agreement for the acquisition of Potters and the Equazen™ brand portfolio from Vifor Pharma  Soho Flordis International (SFI), through its Swiss subsidiary Ginsana SA, will acquire leading UK manufacturer and supplier of traditional herbal treatments Potters, from Vifor Pharma, a company of the Galenica Group.http://www.viforpharma.com/en/Media/mediareleases/2015/20151022_potters-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2015/20151022_potters-message.phpThu, 22 Oct 2015 06:53:38 +0200Vifor Pharma Ltd.A meta-analysis on individual-patient data reports that Ferinject® treatment of iron deficiency in patients with systolic chronic heart failure is associated with reduced rates of cardiovascular hospitalisations and cardiovascular deathsThis meta-analysis, presented at ESC Congress 2015, was performed using the four available completed double-blind trials conducted in ambulatory patients with systolic chronic heart failure (CHF) and iron deficiency (ID) which compared the efficacy and safety of intravenous (i.v.) iron therapy with Ferinject® (ferric carboxymaltose) against placebo. http://www.viforpharma.com/en/Media/mediareleases/2015/20150831_4699793179-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2015/20150831_4699793179-message.phpMon, 31 Aug 2015 11:43:03 +0200Vifor Pharma Ltd.Vifor Fresenius Medical Care Renal Pharma and Relypsa enter into partnership to commercialize Patiromer FOS in Europe and additional territories Vifor Fresenius Medical Care Renal Pharma And Relypsa enter into partnership to commercialize Patiromer FOS in Europe and additional territorieshttp://www.viforpharma.com/en/Media/mediareleases/2015/20150811_7446032208-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2015/20150811_7446032208-message.phpTue, 11 Aug 2015 06:44:34 +0200Vifor Pharma Ltd.Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europehttp://www.viforpharma.com/en/Media/mediareleases/2015/20150528_vifor-fresenius-medical-care-renal-pharma-expansion-of-product-portfolio-and-establishment-of-a-marketing-and-sales-organisation-in-europe.phphttp://www.viforpharma.com/en/Media/mediareleases/2015/20150528_vifor-fresenius-medical-care-renal-pharma-expansion-of-product-portfolio-and-establishment-of-a-marketing-and-sales-organisation-in-europe.phpThu, 28 May 2015 07:09:51 +0200Vifor Pharma Ltd.Velphoro® receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis Velphoro® (polynuclear iron(III)-oxyhydroxide, sucroferric oxyhydroxide), a non-calcium phosphate binder, has received Swissmedic approval for the control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) on dialysis (haemodialysis or peritoneal dialysis).http://www.viforpharma.com/en/Media/mediareleases/2015/20150127_velphoro_swiss_approval.phphttp://www.viforpharma.com/en/Media/mediareleases/2015/20150127_velphoro_swiss_approval.phpTue, 27 Jan 2015 00:00:00 +0100Vifor Pharma Ltd.Vifor Pharma appoints heads of International Business Operations and Global MarketingVifor Pharma today announced the appointments of Dario Eklund as Head of International Business Operations (including North America) and Abdul Mullick as Head of Global Marketing. Both positions will report directly to the CEO of Vifor Pharma Søren Tulstrup and will be based at the headquarters in Zurich, Switzerland.http://www.viforpharma.com/en/Media/mediareleases/2014/20140916_6179647673-leadership.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140916_6179647673-leadership.phpTue, 16 Sep 2014 07:50:44 +0200Vifor Pharma Ltd.CONFIRM-HF study demonstrates that Ferinject® improves exercise capacity in patients with chronic heart failureThe CONFIRM-HF study was designed to compare the efficacy and safety of iron therapy with Ferinject® (ferric carboxymaltose) against placebo in patients with chronic heart failure (CHF) and iron deficiency over one year. The study met its primary endpoint, significant improvement in 6 minute walk test (6MWT) from baseline to week 24 – and also confirmed and complemented, the efficacy and safety profile of Ferinject® observed in the FAIR-HF study*.http://www.viforpharma.com/en/Media/mediareleases/2014/20140901_confirm-hf.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140901_confirm-hf.phpMon, 01 Sep 2014 00:00:00 +0200Vifor Pharma Ltd.Velphoro® receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysisVelphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the control of serum phosphorus levels in adult patients with Chronic Kidney Disease (CKD) on haemodialysis or peritoneal dialysis. In June, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for the product.http://www.viforpharma.com/en/Media/mediareleases/2014/20140827_velphoro-eu-approval.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140827_velphoro-eu-approval.phpWed, 27 Aug 2014 07:22:52 +0200Vifor Pharma Ltd.New faster, cost effective treatment for iron deficiency anaemia now available in New ZealandPatients and healthcare professionals will benefit from greater access to an innovative intravenous iron preparation that is cost effective and substantially faster to administer, with the listing of Ferinject® (ferric carboxymaltose) on the Hospital Medicines List for use in DHB Hospitals.http://www.viforpharma.com/en/Media/mediareleases/2014/20140730_2363569952-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140730_2363569952-message.phpWed, 30 Jul 2014 00:00:00 +0200Vifor Pharma Ltd.Velphoro® (PA21) recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysisVelphoro® (sucroferric oxyhydroxide) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation for the control of serum phosphorus levels in adult patients with Chronic Kidney Disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). The final decision on the approval by the European Commission is expected in autumn 2014.http://www.viforpharma.com/en/Media/mediareleases/2014/20140626_8603057854-recommendation-velphoro.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140626_8603057854-recommendation-velphoro.phpFri, 27 Jun 2014 00:00:00 +0200Vifor Pharma Ltd.Faster, more affordable treatment for Iron Deficiency Anaemia now available in AustraliaPatients and healthcare professionals will benefit from greater access to an innovative intravenous (i.v.) iron preparation that is 24 times faster to administer than traditional methods, with the listing of Ferinject® (ferric carboxymaltose) on the Pharmaceutical Benefits Scheme (PBS).http://www.viforpharma.com/en/Media/mediareleases/2014/20140602_3088804148-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140602_3088804148-message.phpMon, 02 Jun 2014 00:00:00 +0200Vifor Pharma Ltd.New Website highlights the serious impact of Iron DeficiencyIronDeficiency.com – a new global website – has been launched today to provide patients, carers and healthcare professionals around the world with a comprehensive source of information about the causes, effects and symptoms of iron deficiency.http://www.viforpharma.com/en/Media/mediareleases/2014/20140327_iron-deficiency-website.phphttp://www.viforpharma.com/en/Media/mediareleases/2014/20140327_iron-deficiency-website.phpThu, 27 Mar 2014 09:32:13 +0100Vifor Pharma Ltd.Velphoro® (PA21) receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysisVelphoro® (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis. Velphoro® will be launched in the US by Fresenius Medical Care North America in 2014.http://www.viforpharma.com/en/Media/mediareleases/2013/20131128_velphoro-us.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20131128_velphoro-us.phpThu, 28 Nov 2013 07:14:46 +0100Vifor Pharma Ltd.Ferinject® reduces or delays requirement for alternative anaemia management compared with oral iron therapy: FIND-CKD study presented at the American Society of Nephrology (ASN) Kidney Weekhttp://www.viforpharma.com/en/Media/mediareleases/2013/20131111_find-ckd-131111.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20131111_find-ckd-131111.phpMon, 11 Nov 2013 07:28:06 +0100Vifor Pharma Ltd.Vifor Pharma and Zeria Pharmaceutical Co., Ltd. enter into an exclusive licensing agreement for Ferinject® in JapanVifor Pharma, a company of the Galenica Group, today announced that it entered into an exclusive licensing agreement with Zeria Pharmaceutical Co., Ltd. for the development and commercialization of Ferinject® (ferric carboxymaltose) for the treatment of iron deficiency anaemia in Japan. http://www.viforpharma.com/en/Media/mediareleases/2013/20130813_partnership-zeria.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130813_partnership-zeria.phpTue, 13 Aug 2013 00:00:00 +0200Vifor Pharma Ltd.Injectafer® receives US FDA approval for the treatment of Iron Deficiency AnaemiaInjectafer® has received US Food and Drug Administration (FDA) approval for the treatment of Iron Deficiency Anaemia (IDA). Luitpold Pharmaceuticals, Inc., the US partner of Vifor Pharma, a company of the Galenica Group, will immediately launch the product. Injectafer® will be produced at the Luitpold manufacturing facility in Columbus, Ohio.http://www.viforpharma.com/en/Media/mediareleases/2013/20130726_injectafer-us-approval.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130726_injectafer-us-approval.phpFri, 26 Jul 2013 07:14:57 +0200Vifor Pharma Ltd.FIND-CKD study demonstrates that Ferinject® reduces need for alternative anaemia treatmenthttp://www.viforpharma.com/en/Media/mediareleases/2013/20130710_find-ckd_130710.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130710_find-ckd_130710.phpWed, 10 Jul 2013 07:19:40 +0200Vifor Pharma Ltd.Helsinn and Vifor Pharma sign Licensing and Distribution agreement for Netupitant-Palonosetron fixed dose combinationhttp://www.viforpharma.com/en/Media/mediareleases/2013/20130516_message-130516.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130516_message-130516.phpThu, 16 May 2013 07:41:43 +0200Vifor Pharma Ltd.PDUFA action date for PA21 New Drug Application set by US FDAPDUFA action date for PA21 New Drug Application set by US FDAhttp://www.viforpharma.com/en/Media/mediareleases/2013/20130415_pdufa_date_pa21.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130415_pdufa_date_pa21.phpMon, 15 Apr 2013 00:00:00 +0200Vifor Pharma Ltd.New PDUFA action date announced by the US FDA for Injectafer® New Drug ApplicationNew PDUFA action date announced by the US FDA for Injectafer® New Drug Applicationhttp://www.viforpharma.com/en/Media/mediareleases/2013/20130408_pdufa-injectafer.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130408_pdufa-injectafer.phpMon, 08 Apr 2013 07:20:18 +0200Vifor Pharma Ltd.PA21 authorisation application submitted in SwitzerlandAn application for the authorisation of PA21 in Switzerland has been submitted to the Swiss Agency for Therapeutic Products (Swissmedic). The application in Switzerland follows the recent submission of a New Drug Application for PA21 in the United States, acceptance of the Marketing Authorisation Application by the European Medicines Agency (EMA) in the European Union and a regulatory submission in Singapore.http://www.viforpharma.com/en/Media/mediareleases/2013/20130312_pa21-swissmedic.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130312_pa21-swissmedic.phpTue, 12 Mar 2013 00:00:00 +0100Vifor Pharma Ltd.PA21 dossier submitted for approval to US FDAThe New Drug Application (NDA) for PA21 has been submitted to the US Food and Drug Administration (FDA). Separately, the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA), which was submitted in December 2012 to seek approval in the European Union. The filing for Singapore was submitted at the beginning of 2013 and further submissions for approval are being prepared. http://www.viforpharma.com/en/Media/mediareleases/2013/20130211_pa21-submission-fda.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130211_pa21-submission-fda.phpMon, 11 Feb 2013 07:18:30 +0100Vifor Pharma Ltd.Observational study suggests a role for Ferinject® (ferric carboxymaltose) in optimizing the care of anaemic and iron deficient patients with cancerOn the eve of World Cancer Day, Vifor Pharma notes the publication of an observational study in routine oncological and haematological settings encompassing anaemic and iron-deficient patients with a wide variety of tumours (420 subjects, efficacy population). http://www.viforpharma.com/en/Media/mediareleases/2013/20130131_media-release-310113.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130131_media-release-310113.phpThu, 31 Jan 2013 07:35:00 +0100Vifor Pharma Ltd.Vifor Pharma and China Medical System Holdings Limited sign distribution agreement for Maltofer® and Uro-Vaxom® in ChinaVifor Pharma, a company of the Galenica Group, today announced that it has entered into an exclusive distribution agreement with China Medical System Holdings Limited (CMS) – a leading Chinese pharmaceutical company – for the Vifor Pharma products Maltofer® and Uro- Vaxom®. Under the agreement, CMS will have rights to distribute the products in the People’s Republic of China, excluding Hong Kong, Macao and Taiwan. CMS will also assume responsibility for registering the products in China.http://www.viforpharma.com/en/Media/mediareleases/2013/20130117_media_release_130117.phphttp://www.viforpharma.com/en/Media/mediareleases/2013/20130117_media_release_130117.phpThu, 17 Jan 2013 08:13:06 +0100Vifor Pharma Ltd.PA21 Pivotal phase III data presented at American Society of Nephrology (ASN) Kidney Week demonstrate successful control of hyperphosphatemia with lower pill burden for patientshttp://www.viforpharma.com/en/Media/mediareleases/2012/20121105_051112_pa21.phphttp://www.viforpharma.com/en/Media/mediareleases/2012/20121105_051112_pa21.phpMon, 05 Nov 2012 09:56:06 +0100Vifor Pharma Ltd.Venofer® (Iron Sucrose Injection, USP) receives US FDA approval for Paediatric IndicationVifor Pharma, a company of the Galenica group, is pleased to inform that its US partner Luitpold Pharmaceuticals has received US Food and Drug Administration (FDA) approval for use of Venofer® (Iron Sucrose Injection USP) in paediatric patients. http://www.viforpharma.com/en/Media/mediareleases/2012/20120926_7960335981-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2012/20120926_7960335981-message.phpWed, 26 Sep 2012 10:25:18 +0200Vifor Pharma Ltd.New Guidelines Issued by a Number of Global Medical Committees Prioritise Management of Iron Deficiency to Improve Patient OutcomesThe new Kidney Disease Guideline: Improving Global Outcomes Clinical Practice Guideline for Anaemia in Chronic Kidney Disease (hereafter referred to as the KDIGO Anaemia Guideline 2012)1 emphasises the importance of recognising and treating iron deficiency first in the treatment of anaemia.http://www.viforpharma.com/en/Media/mediareleases/2012/20120917_5595830467-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2012/20120917_5595830467-message.phpMon, 17 Sep 2012 11:09:07 +0200Vifor Pharma Ltd.PA21: Pivotal phase III study met primary and secondary endpoints - Preparations for regulatory filings are under wayThe study investigated the use of PA21 (iron(III)-oxyhydroxide) in treating hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. The study met its primary and secondary endpoints, and will be used as the basis for regulatory filings in the USA, Europe and Switzerland.http://www.viforpharma.com/en/Media/mediareleases/2012/20120709_pa21_phase_3_study.phphttp://www.viforpharma.com/en/Media/mediareleases/2012/20120709_pa21_phase_3_study.phpMon, 09 Jul 2012 07:24:23 +0200Vifor Pharma Ltd.Debiopharm and Vifor Pharma sign an exclusive agreement Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland http://www.viforpharma.com/en/Media/mediareleases/2012/20120515_8319385022-message.phphttp://www.viforpharma.com/en/Media/mediareleases/2012/20120515_8319385022-message.phpTue, 15 May 2012 09:50:08 +0200Vifor Pharma Ltd.A single 1,000 mg dose of Ferinject® rapidly improves fatigue symptoms in iron deficient, non-anaemic womenResults of a new clinical study show that a single 1,000 mg dose of the intravenous iron treatment Ferinject® rapidly improves fatigue in symptomatic iron deficient, non-anaemic women.http://www.viforpharma.com/en/Media/mediareleases/2012/20120417_5026766308_message.phphttp://www.viforpharma.com/en/Media/mediareleases/2012/20120417_5026766308_message.phpTue, 17 Apr 2012 07:51:19 +0200Vifor Pharma Ltd.Preoperative Anaemia Increases the Risk of Death and Major Morbidity in Surgical Patientshttp://www.viforpharma.com/en/Media/mediareleases/2011/20111007_820054499_message.phphttp://www.viforpharma.com/en/Media/mediareleases/2011/20111007_820054499_message.phpFri, 07 Oct 2011 11:50:39 +0200Vifor Pharma Ltd.Vifor Pharma and Hikma Pharmaceuticals to collaborate in Middle East and North Africahttp://www.viforpharma.com/en/Media/mediareleases/2011/20110817_439943873_message.phphttp://www.viforpharma.com/en/Media/mediareleases/2011/20110817_439943873_message.phpWed, 17 Aug 2011 06:53:17 +0200Vifor Pharma Ltd.Ferinject® receives MHRA approval for a simplified dosing regimen for the treatment of iron deficiencyhttp://www.viforpharma.com/en/Media/mediareleases/2011/20110713_663502800_message.phphttp://www.viforpharma.com/en/Media/mediareleases/2011/20110713_663502800_message.phpWed, 13 Jul 2011 17:27:31 +0200Vifor Pharma Ltd.Intravenous iron improves fatigue in iron deficient non-anemic patients: the FERRIM studyhttp://www.viforpharma.com/en/Media/mediareleases/2011/20110711_918690634_message.phphttp://www.viforpharma.com/en/Media/mediareleases/2011/20110711_918690634_message.phpMon, 11 Jul 2011 13:34:44 +0200Vifor Pharma Ltd.SMC approves Ferinject® (ferric carboxymaltose) for the treatment of iron deficiency anaemiaThe Scottish Medicines Consortium (SMC) has today recommended the use of Vifor Pharma’s Ferinject® (ferric carboxymaltose), the intravenous (I.V.) iron for the treatment of iron deficiency anaemia (IDA) when oral iron preparations are ineffective or cannot be used. http://www.viforpharma.com/en/Media/mediareleases/2011/20110707_708029979_smc-approves-ferinject.phphttp://www.viforpharma.com/en/Media/mediareleases/2011/20110707_708029979_smc-approves-ferinject.phpMon, 13 Jun 2011 00:00:00 +0200Vifor Pharma Ltd.